Researchers at the Vall d'Hebron Hospital Research Institute have discovered that the levels of a protein called aprataxin are related to patient response to irinotecan, a drug used in the chemotherapy of patients with colon cancer.

This molecule could be used as a marker to better guide the treatment of patients with colon cancer, thus increasing their survival. This discovery, led by CIBBIM researchers, has been carried out in collaboration with CIBER-BBN (CIBER de Bioingeniería, Biomateriales y Nanomedicina) and the results of the study have been published in the journal Clinical Cancer Research.